Unichem Laboratories Ltd Falls 2.03%: Valuation Shift and 52-Week Low Mark a Challenging Week

16 February 2026: Weak Start Amid Market Gains

Unichem Laboratories began the week with a sharp decline, closing at Rs.367.50, down 2.42% from the previous close of Rs.376.60. This drop occurred despite the Sensex rising 0.70% to 36,787.89, highlighting early investor caution. The stock’s volume was relatively low at 627 shares, reflecting subdued trading interest. The decline was consistent with the company’s ongoing financial headwinds, including rising debt servicing costs and weak profitability metrics.

17 February 2026: Mojo Grade Upgrade on Valuation Grounds

On 17 February, Unichem Laboratories’ Mojo Grade was upgraded from Strong Sell to Sell by MarketsMOJO, driven primarily by improved valuation metrics despite persistent financial challenges. The stock price rebounded to Rs.372.95, gaining 1.48% on the day, while the Sensex also advanced 0.32% to 36,904.38. The upgrade reflected a shift in valuation grade from Attractive to Very Attractive, with the company trading at a price-to-earnings ratio of 24.64, significantly lower than peers such as Ajanta Pharma (PE 36.05) and Gland Pharma (PE 34.38).

Despite this positive valuation shift, Unichem’s profitability remained under pressure, with return on capital employed at 4.90% and return on equity at 6.03%. The company’s debt to EBITDA ratio remained elevated at 4.87 times, underscoring ongoing leverage concerns. The stock’s modest recovery on this day was a technical response to the rating upgrade but did not fully offset the prior day’s losses.

18 February 2026: Marginal Gains Amid Steady Market

The stock edged up slightly to Rs.374.10, a 0.31% gain, while the Sensex rose 0.43% to 37,062.35. Trading volume was low at 536 shares, indicating limited momentum. The modest price increase followed the previous day’s upgrade but did not signal a sustained recovery. Unichem’s valuation remained attractive relative to peers, with a PEG ratio of 0.83 suggesting undervaluation relative to earnings growth potential. However, operational returns and profitability metrics continued to weigh on sentiment.

19 February 2026: Sharp Decline on Market Weakness

Unichem Laboratories’ stock fell sharply by 1.71% to Rs.367.70, underperforming the Sensex which declined 1.45% to 36,523.88. The volume was particularly low at 280 shares, reflecting cautious trading. This drop coincided with broader market weakness and highlighted the stock’s vulnerability amid ongoing financial pressures. The stock’s technical indicators remained negative, trading below key moving averages and signalling sustained downward momentum.

20 February 2026: New 52-Week Low Amid Financial Concerns

The stock hit a fresh 52-week low of Rs.360.55 during intraday trading before closing at Rs.368.95, up 0.34% from the previous day’s close but still down 2.03% for the week. This new low underscored persistent investor concerns about the company’s financial health, including a high debt to EBITDA ratio of 4.87 and a sharp decline in quarterly profits. The December 2025 quarter saw profit before tax excluding other income fall 77.2% to Rs.6.11 crore, while net profit after tax dropped 56.0% to Rs.16.13 crore. Interest expenses increased by 30.5% over six months, adding pressure on earnings.

Despite these challenges, Unichem has demonstrated steady long-term sales growth at 11.95% annually over five years and operating profit growth of 148.09% annually, suggesting operational improvements. However, the stock’s recent underperformance relative to the Sensex and sector peers remains a cautionary signal.

Key Takeaways

Unichem Laboratories Ltd’s week was characterised by a modest decline of 2.03% in share price, underperforming the Sensex’s 0.39% gain. The upgrade in Mojo Grade from Strong Sell to Sell on 17 February reflected improved valuation metrics, including a PE ratio of 24.64 and a PEG ratio of 0.83, signalling price attractiveness relative to earnings growth potential.

However, the company’s financial health remains a concern. Elevated debt levels, with a debt to EBITDA ratio of 4.87, and declining quarterly profits have weighed on investor sentiment. The stock’s fall to a 52-week low of Rs.360.55 on 20 February underscores these challenges. Operational returns remain modest, with ROCE at 4.90% and ROE at 6.03%, limiting confidence in near-term recovery.

Long-term sales and operating profit growth rates are encouraging, but the disconnect between earnings growth and share price performance highlights market caution. The stock trades near the lower end of its 52-week range, suggesting a valuation reset that may attract value-focused investors, albeit with significant risk considerations.

Conclusion

The week’s developments for Unichem Laboratories Ltd illustrate a complex picture of valuation appeal tempered by financial and operational headwinds. While the Mojo Grade upgrade to Sell signals some improvement in market perception, the stock’s continued underperformance and new 52-week low reflect persistent challenges. Investors should remain mindful of the company’s elevated leverage, subdued profitability, and recent earnings declines when assessing the stock’s prospects. The divergence between valuation attractiveness and fundamental weaknesses suggests a cautious stance remains warranted in the near term.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today